An ongoing dialogue on HIV/AIDS, infectious diseases,
April 14th, 2010
Maraviroc Rarely Used for Treatment-Naive Patients
Over in Journal of Infectious Diseases, the MERIT study was recently published (with Chuck Hicks’ Journal Watch summary here), demonstrating that maraviroc is non-inferior to efavirenz — provided that the enhanced-sensitivity tropism test is used to select appropriate candidates.
(The MERIT study began in 2004-5. Don’t think I’ll ever forget that, since the investigator meeting overlapped with this memorable series. Notable event pictured.)
Despite these favorable results from the trial — and the FDA approval of the drug for treatment-naive patients — I agree with Chuck that mariviroc will get little use in this population, if only because the “preferred” alternatives (efavirenz, atazanavir/r, darunavir/r, raltegravir) are so incredibly good.
Our reader poll (right side of page) confirms how rarely the drug is prescribed as initial therapy. I suspect that some of the respondents who said they have given the drug to these patients did so within a clinical trial, which would make the response even lower.
Will maraviroc — or another CCR5 antagonist — ever have widespread use in HIV treatment?
Call me an optimist, but I envision that these drugs will be part of an aggressive eradication strategy, somehow based on the remarkable case of “cure” following bone marrow transplantation from a CCR5-negative donor.
Hey, I can dream can’t I? Red Sox fans certainly did in 2004.
Paul E. Sax, MD
Associate Editor
NEJM Clinician
Biography | Disclosures & Summaries
Learn more about HIV and ID Observations.
FROM NEJM — Recent Infectious Disease Articles- From Crisis to Action — Policy Pathways to Reverse the Rise in Congenital Syphilis December 13, 2025In recent years, cases of congenital syphilis have surged. This trend reflects both prenatal care gaps and systemic issues, including failures in testing, treatment, and public health infrastructure.
- High-Dose Influenza Vaccine to Reduce Hospitalizations December 11, 2025In adults 65 to 79 years of age, there appeared to be fewer hospitalizations for influenza or pneumonia with high-dose influenza vaccine than with the standard dose, with a similar incidence of serious adverse events.
- History of Medicine: Smallpox at the Siege of Boston, November 1775–March 1776 December 11, 2025Smallpox played a pivotal role throughout the American Revolution, but the record remains ambiguous about whether British officers weaponized refugees to sow pestilence in the Continental Army.
- Current and Emerging Approaches to Evaluating Influenza Vaccine Performance December 11, 2025Randomized, placebo-controlled trials are widely accepted as the scientific reference standard to determine a causal association between an intervention and an outcome. They are pivotal for product licensure. Although such trials establish safety and efficacy with the assumption that bias has been eliminated, limitations remain. For vaccines, establishing the duration...
- High-Dose Influenza Vaccine Effectiveness against Hospitalization in Older Adults December 11, 2025Among adults 65 years of age or older, a high-dose influenza vaccine did not result in a significantly lower incidence of hospitalization for influenza or pneumonia than a standard-dose vaccine.
- From Crisis to Action — Policy Pathways to Reverse the Rise in Congenital Syphilis December 13, 2025